813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial
Jean‐Sébastien Frenel, JW Kim, Dominique Berton-Rigaud, Rebecca Asher, Laura Vidal, Patricia Pautier, JA Ledermann, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Nicoletta Colombo, TW Park-Simon, Kohei Tamura, Gabe S. Sonke, Alison Freimund, Chee Khoon Lee, Éric Pujade-Lauraine
Topics & Concepts
MedicineOlaparibChemotherapyInternal medicinePlaceboProgression-free survivalOncologyOvarian cancerGastroenterologySurgeryCancerPathologyPoly ADP ribose polymerasePolymeraseBiochemistryGeneChemistryAlternative medicinePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancer